title: The role of tumour microenvironment in gastric cancer angiogenesis.
abstract: Gastric cancer is one of the most common cancers in the world. More than 95% of gastric cancers are adenocarcinomas originating from the glandular epithelium of the stomach lining. Unfortunately, a large number of patients are diagnosed when the tumour is at unresectable stage. Therefore, it is very important to understand the mechanisms involved in gastric cancer pathogenesis. One of them is angiogenesis, which means the formation of new blood vessels from pre-existing vasculature. This process is dependent on interactions between the tumour and surrounding stromal cells which create the tumour microenvironment. Moreover, both tumour and stromal cells release a wide array of angiogenic factors that have an influence on endothelial cell recruitment and thus affect the process of angiogenesis. In this paper we discuss the role of tumour microenvironment in gastric cancer angiogenesis.
authors: Chair and Department of Histology and Embryology, Faculty of Medicine and Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.
authors: Marlena
authors: M
authors: Brzozowa
authors: Chair and Department of Histology and Embryology, Faculty of Medicine and Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.
authors: Marek
authors: M
authors: Michalski
authors: Chair and Department of Histology and Embryology, Faculty of Medicine and Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.
authors: Marzena
authors: M
authors: Harabin-Słowińska
authors: Chair and Department of Histology and Embryology, Faculty of Medicine and Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.
authors: Romuald
authors: R
authors: Wojnicz
keywords: angiogenesis; gastric cancer; tumour microenvironment
references: J Gastroenterol. 2008;43(3):216-24
references: 18373164
references: World J Gastroenterol. 2012 Mar 7;18(9):979-85
references: 22408359
references: Ann Oncol. 2008 Sep;19(9):1523-9
references: 18441328
references: Clin Cancer Res. 1998 Feb;4(2):429-34
references: 9516932
references: Br J Cancer. 1999 Oct;81(4):647-53
references: 10574250
references: Histopathology. 2009 Mar;54(4):442-51
references: 19309396
references: Cancer Microenviron. 2010 Dec;3(1):109-16
references: 20020278
references: Cancer Res. 2006 Jan 15;66(2):605-12
references: 16423985
references: Biochem Pharmacol. 2011 May 15;81(10):1183-91
references: 21382350
references: Clin Cancer Res. 2005 Nov 1;11(21):7629-36
references: 16278381
references: Eur J Surg Oncol. 2010 Dec;36(12):1172-9
references: 20888167
references: Br J Cancer. 2011 Sep 27;105(7):996-1001
references: 21863023
references: Eur J Cancer. 2004 Jun;40(9):1302-13
references: 15177488
references: J Biol Chem. 2008 Jul 11;283(28):19864-71
references: 18495668
references: J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
references: 1688381
references: Curr Cancer Drug Targets. 2009 Aug;9(5):639-51
references: 19508171
references: Pharmacol Ther. 2010 Jan;125(1):105-17
references: 19874848
references: Semin Cell Dev Biol. 2010 Feb;21(1):19-25
references: 19857592
references: World J Surg. 2011 May;35(5):1010-6
references: 21387130
references: Clin Gastroenterol Hepatol. 2006 Apr;4(4):416-25
references: 16616344
references: Int J Cancer. 2011 May 1;128(9):2038-49
references: 20648559
references: Med Sci Monit. 2012 Apr;18(4):BR130-4
references: 22460086
references: Anticancer Res. 2005 Jan-Feb;25(1B):463-70
references: 15816613
references: Prostaglandins Leukot Essent Fatty Acids. 2008 Feb;78(2):137-46
references: 18093816
references: Cell Cycle. 2006 Aug;5(15):1597-601
references: 16880743
references: Eur J Cancer. 1998 Aug;34(9):1439-47
references: 9849429
references: J Surg Oncol. 2012 Sep 15;106(4):462-8
references: 22488237
references: Cell. 2005 May 6;121(3):335-48
references: 15882617